Message from Renovaro Biosciences CEO, The Hon. Mark Dybul, MD
October 02, 2023 12:05 ET
|
Renovaro Biosciences Inc.
LOS ANGELES, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (Nasdaq: RENB) Dear Shareholders, I am writing to provide you with an update on our recent news of signing a definitive...
AI Company GEDiCube and Renovaro Biosciences Sign Definitive Agreement to Combine
October 02, 2023 09:25 ET
|
Renovaro Biosciences Inc.
Message from Renovaro Biosciences CEO, The Hon. Mark Dybul, MD LOS ANGELES, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (Nasdaq: RENB) Dear Shareholders, I am writing to provide...
Interim results for the six months ended 30 June 2023
September 29, 2023 16:30 ET
|
Biodexa Pharmaceuticals PLC
29 September 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Interim results for the six months ended 30 June 2023 Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage...
Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application
September 27, 2023 08:00 ET
|
Vaccinex, Inc.
Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting New ActivMAb® application to be reviewed on September 28 at CHI's 20th Annual Discovery on...
Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)
September 21, 2023 08:30 ET
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at...
Journal of Cellular and Molecular Medicine Publishes Preclinical Data of Panavance’s GP-2250 to treat Pancreatic Cancer
September 12, 2023 07:07 ET
|
Panavance Therapeutics Inc.
Results showed antineoplastic activity in pancreatic tumor cell lines Metabolic and transcriptional findings demonstrate a molecular basis to reduce tumor cell proliferation and induce apoptotic cell...
Sapu BioScience and Cromos Pharma initiating P201 – A Registrational trial for OT-101 in Pancreatic Cancer
August 23, 2023 07:10 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced today its joint venture partner, GMP...
Pancreatic Cancer Market to Surpass USD 7,400 Million by 2032
August 14, 2023 11:57 ET
|
Precedence Research
Ottawa, Aug. 14, 2023 (GLOBE NEWSWIRE) -- The global pancreatic cancer market revenue is projected to reach around USD 5,040 million by 2029, a study published by Towards Healthcare a sister firm of...
FibroGen Reports Second Quarter 2023 Financial Results
August 07, 2023 16:01 ET
|
FibroGen, Inc.
Topline data from three late-stage pamrevlumab trials expected through 1H 2024, including the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in metastatic pancreatic...
Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 03, 2023 16:05 ET
|
Immuneering Corporation
- Positive initial pharmacokinetic, pharmacodynamic and safety data presented at American Association for Cancer Research (AACR) annual meeting, with IMM-1-104 demonstrating Cmax, half-life, and...